Company news

Guardant Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

February 1, 2023

Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

January 31, 2023

Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery

January 30, 2023

Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer

January 29, 2023

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer

January 18, 2023

Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers

January 16, 2023

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results

January 8, 2023

Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 27, 2022

Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

December 20, 2022

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

December 14, 2022

Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer

December 7, 2022

Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients

November 30, 2022

Guardant Health Reports Third Quarter 2022 Financial Results

November 2, 2022

Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022

October 9, 2022

Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

September 8, 2022

Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients

September 5, 2022

Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics

August 30, 2022

Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference

August 28, 2022

Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers

August 14, 2022

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations

August 11, 2022

Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

August 4, 2022

Guardant Health Reports Second Quarter 2022 Financial Results

August 3, 2022

Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test

August 1, 2022

Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022

July 12, 2022

Steve E. Krognes Joins Guardant Health Board of Directors

July 6, 2022

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

July 5, 2022

Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture

June 12, 2022

Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022

May 20, 2022

Guardant Health Reports First Quarter 2022 Financial Results

May 4, 2022

Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults

May 1, 2022

Guardant Health to Report First Quarter Financial Results on May 5, 2022

April 12, 2022

Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting

April 10, 2022

Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests

April 3, 2022

Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan

March 13, 2022

Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test

March 7, 2022

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook

February 22, 2022

Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

January 17, 2022

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer

December 16, 2021

Guardant Health Reports Third Quarter 2021 Financial Results

November 3, 2021

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

November 2, 2021

Guardant Health Appoints Myrtle Potter to Its Board of Directors

October 19, 2021

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

October 7, 2021

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers

October 4, 2021

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

August 4, 2021

Guardant Health to Report Second Quarter Financial Results on August 5, 2021

July 12, 2021

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

June 21, 2021

CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

June 17, 2021

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

June 7, 2021

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

May 27, 2021

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 20, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.